It's time to move
the needle on
reducing non-unions.
Today, nearly 1 in 5 fusions end in failure.
But we have the power to change it.
MagnetOs isn't like other bone grafts. It
grows bone even in soft tissue thanks to our
unique NeedleGrip
TM
surface technology
which provides traction for our body's vitally
important 'pro-healing' immune cells (M2
macrophages).
*†1
This in turn, unlocks previously untapped
potential to stimulate stem cells - and form
new bone throughout the graft.
The growing body of science behind
MagnetOs is called osteoimmunology.
2-4
But for surgeons and their patients it means
one thing: a more efficient and predictable
fusion.
*
So, are you ready to move the needle?
Get in touch with us today at:
findoutmore.kurosbio.com/beckers-spine-21
References: 1. Duan, et al. eCM. 2019;37:60-73. 2. Van Dijk, et al. eCM. 2021;41:756-73. 3. Van Dijk, et al. JOR Spine. 2018;e1039. 4. Van Dijk, et al. J Biomed Mater Res. Part B: Appl Biomater. 2019;107(6):2080-2090.
*MagnetOs has been proven to generate more predictable fusions than two commercially available alternatives in an ovine model of posterolateral fusion. Results from in vivo laboratory testing may not be predictive of clinical experience
in humans. For important safety and intended use information please visit kurosbio.com.
†
MagnetOs is not cleared by FDA as an osteoinductive bone graft.
Manufactured by Kuros Biosciences BV, Prof Bronkhorstlaan 10, Building 48, 3723 MB Bilthoven, The Netherlands.
MagnetOs and NeedleGrip are trademarks of Kuros Biosciences.
PROMO/MAG/US/029-21/R00
Aug
'21
PROMO_MAG_US_029-21_R00.indd 1 PROMO_MAG_US_029-21_R00.indd 1 01-10-2021 10:47 01-10-2021 10:47
